Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: Adults and paediatric patients with moderately to severely active CD or UC who have had an...), Ulcerative Colitis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Non-Infectious Uveitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
US
  • Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate.
  • Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Product first approved 2002Outside this platform's coverageFDA label
JP
  • Treatment of rheumatoid arthritis (for use only when conventional therapies are not sufficiently effective)
Product first approved 2008PMDA
CA
  • Humira is indicated for: Rheumatoid Arthritis  reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira can be used alone or in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs). When used as first-line treatment in recently diagnosed patients who have not been previously treated with methotrexate, Humira should be given in combination with methotrexate....
Product first approved 2004Health Canada
UK
  • Moderate to severely active Crohn's disease and ulcerative colitis in adults and paediatric patients
Product first approved 2003medicines.org.uk
EU
  • Please refer to the product information document.
Product first approved 2003EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (115)
Crohn's Disease
NCT02332356 · Tokyo Medical and Dental University
2014-09 – 2024-03 · Crohn Disease
What this study did
NCT01986127 · Sara Varea
2014-02-14 – 2018-06-30 · Crohn's Disease
What this study did
NCT01629628 · Tel-Aviv Sourasky Medical Center
2012-07 – 2016-07 · Crohn Disease
What this study did
NCT01674413 · Peter Higgins
2013-10 – 2016-03 · Crohn's Disease
What this study did
NCT01562951 · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012-10 – 2014-03 · Crohn's Disease, Mucosal Inflammation
What this study did
NCT00736983 · Foundation for Liver Research
2008-09 – 2011-12 · Crohn's Disease With Perianal Fistulas
What this study did
NCT00077779 · Abbott
started 2003-07 · Crohn's Disease
What this study did
Hidradenitis Suppurativa
NCT02904902 · AbbVie
2016-09-06 – 2019-05-30 · Hidradenitis Suppurativa
What this study did
NCT01635764 · AbbVie (prior sponsor, Abbott)
2012-04 – 2016-08 · Hidradenitis Suppurativa
What this study did
NCT01468233 · AbbVie (prior sponsor, Abbott)
2011-11 – 2014-04 · Hidradenitis Suppurativa (HS)
What this study did
Non-Infectious Uveitis
NCT06258915 · Assistance Publique - Hôpitaux de Paris
2024-03-01 – 2027-11-01 · Non Infectious Uveitis
What this study did
Psoriasis
NCT05495568 · Celltrion
2022-11-07 – 2024-02-05 · Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT05637515 · Biocon Biologics Inc.
2022-11-21 – 2023-09-19 · Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
What this study did
NCT04453137 · Alvotech Swiss AG
2020-06-30 – 2021-11-16 · Plaque Psoriasis
What this study did
NCT03849404 · Alvotech Swiss AG
2019-02-20 – 2020-07-20 · Plaque Psoriasis
What this study did
NCT02533375 · AbbVie
2015-09-28 – 2017-07-20 · Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese
What this study did
NCT02581345 · Momenta Pharmaceuticals, Inc.
2015-09 – 2017-04-04 · Chronic Plaque Psoriasis, Psoriasis
What this study did
NCT02196701 · AbbVie
2014-08-05 – 2017-03-17 · Psoriasis
What this study did
NCT02016482 · AbbVie
2014-01 – 2016-04 · Nail Psoriasis, Plaque Psoriasis
What this study did
NCT01251614 · AbbVie (prior sponsor, Abbott)
2010-12 – 2015-02 · Plaque Psoriasis
What this study did
NCT01646073 · AbbVie (prior sponsor, Abbott)
2012-08 – 2013-12 · Plaque Psoriasis
What this study did
NCT00566722 · Abbott
2008-01 – 2009-04 · Psoriasis
What this study did
NCT00927069 · Innovaderm Research Inc.
2007-03 – 2008-12 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT00195689 · Abbott
started 2003-08 · Psoriatic Arthritis
What this study did
NCT00235885 · Abbott
started 2005-07 · Psoriatic Arthritis
What this study did
Phase 2/3 (13)
Crohn's Disease
Psoriasis
NCT03217734 · Jeffrey J Crowley MD
2017-04-10 – 2018-12-31 · Psoriasis
What this study did
NCT00647400 · Abbott
2006-04 – 2010-04 · Psoriasis
What this study did
NCT00338754 · Abbott
started 2005-11 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT05172817 · Institute for Developing Science and Health Initiatives, Bangladesh
2021-06-02 – 2022-10-30 · Pharmacokinetics, Safety, Efficacy, Rheumatoid Arthritis
What this study did
NCT00538902 · Abbott
2007-08 – 2009-12 · Rheumatoid Arthritis
What this study did
NCT00647491 · Abbott
2004-02 – 2005-08 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT05299242 · University of Oxford
2022-07-21 – 2023-06-12 · Frozen Shoulder
What this study did
NCT01385826 · Assistance Publique - Hôpitaux de Paris
2011-06-29 – 2015-08-27 · Uveitis, Juvenile Arthritis
What this study did
NCT00348153 · Heidelberg University
2006-08 – 2013-03 · Uveitis
What this study did
NCT00235105 · Charite University, Berlin, Germany
2005-03 – 2007-06 · Ankylosing Spondylitis
What this study did
Phase 2 (58)
Crohn's Disease
NCT04655807 · Janssen Research & Development, LLC
2021-03-03 – 2023-09-04 · Crohn Disease
What this study did
NCT00055523 · Abbott
started 2002-04 · Crohn's Disease
What this study did
Hidradenitis Suppurativa
NCT02643654 · Evangelos J. Giamarellos-Bourboulis, M.D.
2015-12 – 2017-02 · Hidradenitis Suppurativa
What this study did
NCT00918255 · Abbott
2009-04 – 2010-11 · Hidradenitis Suppurativa
What this study did
NCT00827996 · Florida Academic Dermatology Centers
2007-02 – 2008-08 · Hidradenitis Suppurativa
What this study did
Non-Infectious Uveitis
NCT05155592 · Dan Liang
2021-01-01 – 2023-04-01 · Uveitis, Adalimumab
What this study did
NCT02706704 · American University of Beirut Medical Center
2016-02 – 2022-01 · Uveitis, Non-Infectious Uveitis
What this study did
NCT00525902 · Oregon Health and Science University
2008-01 – 2010-09 · Uveitis
What this study did
Psoriasis
NCT01872546 · Poitiers University Hospital
2013-01 – 2013-09 · Chronic Plaque Psoriasis
What this study did
NCT00645905 · Abbott
2003-06 – 2005-03 · Psoriasis
What this study did
NCT00645892 · Abbott
2003-11 – 2004-09 · Psoriasis
What this study did
NCT00646191 · Abbott
2003-03 – 2004-06 · Psoriasis
What this study did
NCT00645814 · Abbott
2003-03 – 2003-09 · Psoriasis
What this study did
Psoriatic Arthritis
Rheumatoid Arthritis
NCT03938701 · University Medical Center Groningen
2024-08-06 – 2026-08-01 · IBD, Rheumatoid Arthritis
What this study did
NCT02393378 · Takeda
2015-04-08 – 2016-11-16 · Rheumatoid Arthritis
What this study did
NCT02565810 · Samsung Bioepis Co., Ltd.
2015-09 – 2016-03 · Rheumatoid Arthritis
What this study did
NCT01752855 · AbbVie (prior sponsor, Abbott)
2012-12 – 2013-10 · Rheumatoid Arthritis
What this study did
NCT01712178 · AbbVie (prior sponsor, Abbott)
2012-06 – 2013-05 · Rheumatoid Arthritis
What this study did
NCT01502423 · AbbVie (prior sponsor, Abbott)
2012-01 – 2012-11 · Rheumatoid Arthritis
What this study did
NCT01561313 · AbbVie (prior sponsor, Abbott)
2012-03 – 2012-11 · Rheumatoid Arthritis
What this study did
NCT01163617 · AbbVie (prior sponsor, Abbott)
2010-05 – 2010-11 · Rheumatoid Arthritis
What this study did
NCT00235833 · Abbott
2003-06 – 2004-10 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05372939 · Applied Molecular Transport
2021-02-05 – 2022-07-13 · Ulcerative Colitis
What this study did
NCT01716039 · Alimentiv Inc.
2013-06 – 2016-07-18 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07845604 · Daniel Moriarity
2026-11 – 2031-09 · Major Depressive Disorder (MDD)
What this study did
NCT07268534 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Folliculitis Decalvans (FD)
What this study did
NCT06037811 · Tom Appleton
2024-04-15 – 2028-12 · Inflammatory Arthritis, Immune-related Adverse Event
What this study did
NCT06849908 · Peking Union Medical College Hospital
2024-11-08 – 2028-06-30 · Behcet Syndrome, Intestinal Type
What this study did
NCT06062875 · Endeavor Health
2024-01-24 – 2028-06-01 · Benign Prostatic Hyperplasia (BPH)
What this study did
NCT05590455 · ANRS, Emerging Infectious Diseases
2023-04-11 – 2027-12 · Tuberculous Meningitis, HIV I Infection
What this study did
NCT06941376 · University of Pennsylvania
2025-11-11 – 2027-12 · Relapsing Polychondritis
What this study did
NCT05874505 · Assistance Publique - Hôpitaux de Paris
2023-07 – 2027-07 · Behcet's Uveitis
What this study did
NCT03651518 · Assistance Publique - Hôpitaux de Paris
2020-10-20 – 2025-11-20 · Inflammatory Disease, Autoimmune Diseases
What this study did
NCT04588818 · Sun Yat-sen University
2020-02-01 – 2023-12-31 · Uveitis
What this study did
NCT04009668 · University of Michigan
2019-10-02 – 2023-10-03 · FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
What this study did
NCT02471118 · CARE ARTHRITIS LTD.
2015-03 – 2021-03 · Osteoarthritis, Knee
What this study did
NCT03180957 · University of Oxford
2016-03-02 – 2020-12 · Dupuytren's Disease
What this study did
NCT00690911 · Wake Forest University
— · Sarcoidosis
What this study did
NCT02113904 · Assistance Publique - Hôpitaux de Paris
2014-01-27 – 2017-09-21 · Netherton Syndrome
What this study did
NCT04154852 · University of Leeds
2011-06 – 2017-01-16 · Oligoarthritis
What this study did
NCT00814255 · NYU Langone Health
2008-12 – 2014-02 · Focal Segmental Glomerulosclerosis
What this study did
NCT00274352 · Pariser, Robert J., M.D.
2006-09 – 2012-02 · Sarcoidosis
What this study did
NCT01136252 · Hospital Universitari Vall d'Hebron Research Institute
2010-05 – 2011-10 · Age-Related Macular Degeneration, Choroidal Neovascularization
What this study did
NCT00514982 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-08-07 – 2011-03-08 · Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
What this study did
Phase 1/2 (11)
Crohn's Disease
NCT01275508 · University of Erlangen-Nürnberg Medical School
2011-01 – 2012-04 · Crohn's Disease
What this study did
Psoriasis
NCT01704599 · Wayne State University
2009-01 – 2014-05 · Psoriasis
What this study did
Ulcerative Colitis
NCT07258641 · University Medical Center Groningen
2026-01-15 – 2028-04-01 · Ulcerative Colitis (UC), Crohn Disease (CD)
What this study did
NCT06117423 · University Medical Center Groningen
2024-03 – 2025-06 · Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT07061574 · City of Hope Medical Center
2026-03-10 – 2031-04-15 · Type 1 Diabetes, New Onset
What this study did
NCT07348588 · Centro de Pesquisa Rubens Siqueira
2025-07-10 – 2027-08-01 · Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)
What this study did
NCT03153319 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2017-06-05 – 2027-02 · Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
What this study did
NCT02586831 · Camillo Ricordi and Jay Skyler
2024-06-01 – 2024-06-01 · Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
What this study did
NCT03607903 · Centre for Human Drug Research, Netherlands
2018-07-11 – 2018-10-30 · Pain, Injection Site
What this study did
NCT02437253 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2015-05 – 2016-07 · Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
What this study did
NCT00686439 · University of Alberta
2008-06 – 2010-11 · Osteoarthritis
What this study did
Phase 1 (18)
Rheumatoid Arthritis
NCT00650156 · AbbVie
2007-06 – 2007-10 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT06742606 · Ain Shams University
2025-01-15 – 2026-12-13 · Effect of Drug
What this study did
NCT00421642 · Mayo Clinic
2006-10 – 2008-04 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06926478 · Massachusetts Eye and Ear Infirmary
2026-10-01 – 2028-06-01 · Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
What this study did
NCT06291948 · Laboratorios Richmond S.A.C.I.F.
2022-08-01 – 2023-10-20 · Pharmacokinetics, Safety Issues
What this study did
NCT05884242 · Janssen Research & Development, LLC
2023-05-22 – 2023-08-07 · Healthy
What this study did
NCT04551352 · Hoffmann-La Roche
2020-10-28 – 2022-07-28 · Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
What this study did
NCT04514796 · Samsung Bioepis Co., Ltd.
2020-08-13 – 2021-05-15 · Healthy
What this study did
NCT03849313 · Alvotech Swiss AG
2019-03-20 – 2020-02-17 · Healthy Volunteers
What this study did
NCT03983876 · Alvotech Swiss AG
2019-07-01 – 2019-12-03 · Phase 1
What this study did
NCT03273192 · Cinnagen
2016-10-22 – 2017-08-06 · Bioequivalence, Phase 1
What this study did
NCT02516774 · Gustave Roussy, Cancer Campus, Grand Paris
2014-12 – 2015-12 · Anaplastic Thyroid Cancers
What this study did
NCT02237729 · Pfizer
2014-09 – 2015-03 · Healthy Subjects
What this study did
NCT02144714 · Samsung Bioepis Co., Ltd.
2014-05 – 2014-09 · Healthy
What this study did
NCT00855608 · Rafic Hariri University Hospital
2009-03 – 2013-03 · Uveitis, Diabetic Retinopathy, Choroidal Neovascularization
What this study did
NCT02252809 · Brugmann University Hospital
2008-11 – 2009-07 · Innate Immunity
What this study did
NCT00193648 · Northwell Health
2005-07 – 2007-10 · Focal Glomerulosclerosis
What this study did
Phase 4 (103)
Crohn's Disease
NCT07510191 · Sixth Affiliated Hospital, Sun Yat-sen University
2026-03-01 – 2029-12-31 · Crohn Disease (CD)
What this study did
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did
NCT06045754 · Takeda
2024-04-18 – 2027-06-28 · Crohn's Disease
What this study did
NCT03917303 · Maastricht University Medical Center
2019-12-23 – 2026-09 · Crohn Disease, Inflammatory Bowel Diseases
What this study did
NCT03306446 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2015-03-17 – 2025-03 · CD
What this study did
NCT03172377 · Radboud University Medical Center
2017-05-03 – 2022-10 · Crohn Disease in Remission, Crohn Disease
What this study did
NCT02764762 · Takeda
2017-04-18 – 2022-07-05 · Crohn Disease
What this study did
NCT02852694 · PIBD-Net
2017-02-28 – 2021-06-14 · Crohn's Disease
What this study did
NCT02256462 · Schneider Children's Medical Center, Israel
2015-05-01 – 2019-01-31 · Crohn's Disease
What this study did
NCT02148718 · AbbVie
2014-06 – 2017-01 · Moderate to Severe Crohn's Disease
What this study did
NCT01556672 · Innovaderm Research Inc.
2012-04 – 2016-04 · Plaque Psoriasis, Crohn's Disease
What this study did
NCT00972218 · University of Alberta
2009-07 – 2010-01 · Spondyloarthritis, Crohn's Disease
What this study did
Hidradenitis Suppurativa
NCT04132388 · Wake Forest University Health Sciences
2020-08-20 – 2022-09-07 · Hidradenitis Suppurativa
What this study did
NCT02808975 · AbbVie
2016-07-18 – 2019-10-16 · Hidradenitis Suppurativa (HS)
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT07529925 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-05 – 2028-05 · Severe Plaque Psoriasis in Chinese Children
What this study did
NCT05510063 · Samsung Bioepis Co., Ltd.
2022-08-04 – 2023-05-04 · Plaque Psoriasis
What this study did
NCT05683054 · University Hospital, Ghent
2020-08-11 – 2022-08-22 · Psoriasis
What this study did
NCT04028713 · University Hospital, Ghent
2021-02-16 – 2022-03-22 · Psoriasis Vulgaris
What this study did
NCT00932113 · Tufts Medical Center
2009-06 – 2017-05-01 · Psoriasis
What this study did
NCT01553058 · University of Pennsylvania
2012-07 – 2016-10-27 · Psoriasis, Cardiovascular Disease
What this study did
NCT01866592 · University of Pennsylvania
2013-04 – 2016-10-27 · Psoriasis, Cardiovascular Disease
What this study did
NCT01722214 · Innovaderm Research Inc.
2012-11 – 2016-01 · Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
What this study did
NCT01088165 · Medical University of Vienna
2010-05 – 2014-05 · Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2
What this study did
NCT01644396 · AbbVie (prior sponsor, Abbott)
2012-05 – 2013-09 · Moderate to Severe Plaque Psoriasis
What this study did
NCT01265823 · AbbVie (prior sponsor, Abbott)
2010-10 – 2012-02 · Psoriasis
What this study did
NCT01181570 · Innovaderm Research Inc.
2010-09 – 2011-09 · Psoriasis, Sleep Apnea, Obstructive
What this study did
NCT00940862 · Innovaderm Research Inc.
2009-07 – 2011-08 · Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
What this study did
NCT01237262 · University of Padova
2010-11 – 2010-11 · Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
What this study did
NCT00735787 · Abbott
2008-08 – 2009-09 · Psoriasis
What this study did
Psoriatic Arthritis
NCT03739853 · University of Oxford
2019-05-14 – 2024-10-31 · Psoriatic Arthritis
What this study did
NCT01465438 · Glostrup University Hospital, Copenhagen
2006-11 – 2011-06 · Psoriatic Arthritis
What this study did
NCT00133315 · Hvidovre University Hospital
2004-09 – 2007-04 · Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05626348 · Qilu Hospital of Shandong University
2021-12-22 – 2026-12-31 · Arthritis, Rheumatoid
What this study did
NCT04194827 · Reade Rheumatology Research Institute
2020-03-01 – 2024-12 · Rheumatoid Arthritis
What this study did
NCT01793519 · Georgetown University
2013-01 – 2024-08-30 · Rheumatoid Arthritis
What this study did
NCT04251741 · Reade Rheumatology Research Institute
2020-07-31 – 2024-05-01 · Rheumatoid Arthritis
What this study did
NCT04222920 · Reade Rheumatology Research Institute
2020-03-01 – 2023-09-11 · Rheumatoid Arthritis
What this study did
NCT03619876 · Columbia University
2019-07-10 – 2021-09-15 · Rheumatoid Arthritis, Myocardial Inflammation
What this study did
NCT03505008 · Keio University
2018-04-18 – 2021-05-11 · Rheumatoid Arthritis
What this study did
NCT02374021 · Brigham and Women's Hospital
2016-07 – 2021-05 · Arthritis, Rheumatoid
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT03737708 · Astellas Pharma Korea, Inc.
2019-02-13 – 2020-06-16 · Rheumatoid Arthritis (RA)
What this study did
NCT02878161 · Fen Li
2016-01 – 2019-12 · Rheumatoid Arthritis
What this study did
NCT02035800 · Université de Sherbrooke
2013-05 – 2019-12 · RheumatoId Arthritis
What this study did
NCT02056184 · University of Leeds
2013-12 – 2019-07 · Rheumatoid Arthritis, Targeted Ultrasound
What this study did
Early phase / not applicable (29)
Crohn's Disease
NCT03261102 · waqqas.afif
2017-01-17 – 2025-06-01 · Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases
What this study did
NCT04200547 · University Hospital, Montpellier
2020-01-29 – 2024-06-29 · Crohn Disease
What this study did
NCT02539849 · Hospital Universitari Vall d'Hebron Research Institute
2014-12 – 2017-12-19 · Crohn Disease
What this study did
NCT01144156 · Rabin Medical Center
— · Crohn's Disease
What this study did
Psoriasis
NCT07128472 · South Valley University
2025-08-01 – 2026-02-01 · Psoriasis
What this study did
NCT05889338 · Sohag University
2023-06 – 2024-01 · Psoriasi
What this study did
NCT03389984 · Poitiers University Hospital
2017-11-14 – 2020-06-18 · Psoriasis Vulgaris
What this study did
NCT01320293 · University of North Carolina, Chapel Hill
2011-03 – 2015-03 · Psoriasis
What this study did
NCT00638469 · Medical University of Graz
2008-03 – 2014-12 · Psoriasis
What this study did
NCT01657513 · University Hospital, Gentofte, Copenhagen
2012-06 – 2013-07 · Psoriasis
What this study did
NCT01435265 · Wake Forest University Health Sciences
2010-01 – 2012-04 · Psoriasis
What this study did
NCT00638261 · Medical University of Graz
2008-03 – 2011-08 · Psoriasis
What this study did
Psoriatic Arthritis
NCT07398651 · Tanta University
2026-12-30 – 2026-12-30 · Psoriatic Arthritis, Ultrasound Assessment, TNF
What this study did
NCT06729463 · South Valley University
2024-12-01 – 2025-03-30 · Psoriasis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05090124 · NHS Greater Glasgow and Clyde
2022-11-04 – 2024-11-29 · Rheumatoid Arthritis
What this study did
NCT05460390 · Boston Medical Center
2022-10-26 – 2024-06-30 · Rheumatoid Arthritis
What this study did
NCT03110094 · Rennes University Hospital
2017-03-13 – 2020-01-13 · Rheumatoid Arthritis
What this study did
NCT01197144 · Karolinska Institutet
2010-10 – 2016-11-28 · Arthritis, Rheumatoid, Pain, Fatigue
What this study did
NCT00814866 · Université de Sherbrooke
2008-09 – 2011-03 · Rheumatoid Arthritis
What this study did
NCT00497614 · University Hospital, Tours
2006-05 – 2008-12 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05291039 · Rehab Werida
2022-01-01 – 2023-04-01 · Inflammatory Bowel Diseases
What this study did
NCT04882683 · Shandong Qilu Stem Cells Engineering Co., Ltd.
2021-06-01 – 2022-12-31 · Ulcerative Colitis
What this study did
NCT02634060 · Universitaire Ziekenhuizen KU Leuven
2016-03-31 – 2022-09-05 · Crohn Disease, Colitis, Ulcerative
What this study did
NCT02878083 · Nantes University Hospital
2017-01-11 – 2021-01-01 · ULCERATIVE COLITIS
What this study did
Other / comorbidity
NCT07913750 · Samsung Medical Center
2026-11-15 – 2028-12-31 · Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Panuveitis
What this study did
NCT07491913 · Marmara University
2025-06-15 – 2027-12-15 · Takayasu Arteritis
What this study did
NCT06310837 · Zhongshan Ophthalmic Center, Sun Yat-sen University
2024-03-27 – 2026-07-03 · Uveitis
What this study did
NCT03561649 · University Hospital, Grenoble
2018-06-14 – 2020-05-07 · Spondylitis, Ankylosing
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
Used as active comparator (111)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (55)
Crohn's Disease
NCT03464136 · Janssen Scientific Affairs, LLC
2018-03-29 – 2021-05-21 · Crohn Disease
What this study did
NCT02871635 · Boehringer Ingelheim
2016-09-28 – 2019-05-13 · Crohn Disease
What this study did
NCT01564823 · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012-06 – 2015-01 · Crohn´s Disease
What this study did
Psoriasis
NCT07836283 · University Hospital, Rouen
2026-10-15 – 2030-10-15 · Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis
What this study did
NCT06640517 · Biocad
2024-08-08 – 2028-02 · Plaque Psoriasis
What this study did
NCT06005532 · Mabscale, LLC
2023-10-02 – 2025-12 · Plaque Psoriasis
What this study did
NCT03927352 · Sinocelltech Ltd.
2019-09-05 – 2022-12-31 · Psoriasis
What this study did
NCT02207244 · Janssen Research & Development, LLC
2014-11-03 – 2020-07-01 · Psoriasis
What this study did
NCT02207231 · Janssen Research & Development, LLC
2014-11-26 – 2020-06-17 · Psoriasis
What this study did
NCT03412747 · UCB Biopharma SRL
2018-01-26 – 2020-02-26 · Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
What this study did
NCT03316781 · Shanghai Henlius Biotech
2017-10-27 – 2019-04-22 · Plaque Psoriasis
What this study did
NCT03210259 · Boehringer Ingelheim
2017-07-10 – 2019-04-16 · Psoriasis
What this study did
NCT02762955 · Biocad
2016-12 – 2018-10-15 · Psoriasis
What this study did
NCT02850965 · Boehringer Ingelheim
2016-08-17 – 2018-01-17 · Psoriasis
What this study did
NCT02660580 · Fresenius Kabi SwissBioSim GmbH
2016-02-16 – 2017-12-18 · Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
What this study did
NCT02489227 · Coherus Oncology, Inc.
2015-08 – 2017-03 · Plaque Psoriasis
What this study did
NCT02016105 · Sandoz
2013-12 – 2016-02 · Plaque Type Psoriasis
What this study did
NCT01970488 · Amgen
2013-10-18 – 2015-03-18 · Psoriasis
What this study did
Psoriatic Arthritis
NCT04527380 · Eli Lilly and Company
2021-04-13 – 2029-01 · Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
What this study did
NCT03895203 · UCB Biopharma SRL
2019-04-03 – 2022-07-11 · Psoriatic Arthritis
What this study did
NCT04115748 · Gilead Sciences
2019-12-03 – 2021-05-11 · Psoriatic Arthritis
What this study did
NCT02745080 · Novartis Pharmaceuticals
2017-04-03 – 2019-12-30 · Psoriatic Arthritis
What this study did
NCT01695239 · Eli Lilly and Company
2012-12 – 2017-09 · Psoriasis, Arthritic
What this study did
NCT02714322 · Mylan Inc.
2015-06 – 2017-03 · Psoriasis, Arthritis, Psoriatic
What this study did
NCT01877668 · Pfizer
2014-01-20 – 2015-12-18 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT02332590 · Sanofi
2015-01-28 – 2020-12-29 · Rheumatoid Arthritis
What this study did
NCT03789292 · Celltrion
2018-11-26 – 2020-04-24 · Rheumatoid Arthritis
What this study did
NCT02889796 · Gilead Sciences
2016-08-30 – 2019-06-20 · Rheumatoid Arthritis
What this study did
NCT03052322 · Fresenius Kabi SwissBioSim GmbH
2017-01-31 – 2018-08-27 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT02746380 · LG Life Sciences
2016-04-13 – 2018-02-23 · Arthritis, Rheumatoid
What this study did
NCT02405780 · Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015-06-10 – 2018-01-18 · Arthritis, Rheumatoid
What this study did
NCT02744755 · Sandoz
2016-03-31 – 2017-09-26 · Rheumatoid Arthritis
What this study did
NCT02137226 · Boehringer Ingelheim
2015-01-26 – 2016-10-18 · Arthritis, Rheumatoid
What this study did
NCT02260791 · Fujifilm Kyowa Kirin Biologics Co., Ltd.
2014-12 – 2016-07 · Arthritis, Rheumatoid
What this study did
NCT02167139 · Samsung Bioepis Co., Ltd.
2014-05 – 2015-10 · Rheumatoid Arthritis
What this study did
NCT01710358 · Eli Lilly and Company
2012-10 – 2015-09 · Rheumatoid Arthritis
What this study did
NCT01970475 · Amgen
2013-10 – 2014-11 · Arthritis, Rheumatoid
What this study did
Ulcerative Colitis
NCT02497469 · Takeda
2015-06-29 – 2019-01-18 · Colitis, Ulcerative
What this study did
Other / comorbidity
NCT06333210 · Biocad
2023-12-25 – 2028-02 · Axial Spondyloarthritis
What this study did
NCT04798755 · Hospital San Carlos, Madrid
2022-01-12 – 2025-10-01 · Uveitis
What this study did
Phase 2/3 (1)
Crohn's Disease
NCT03759288 · AstraZeneca
2018-12-07 – 2023-10-18 · Crohn's Disease, IBD
What this study did
Phase 2 (19)
Hidradenitis Suppurativa
NCT07151937 · Almirall, S.A.
2025-11-05 – 2027-11-25 · Hidradenitis Suppurativa
What this study did
NCT05322473 · MoonLake Immunotherapeutics AG
2022-04-25 – 2023-08-30 · Hidradenitis Suppurativa
What this study did
NCT04988308 · Janssen Research & Development, LLC
2021-10-12 – 2022-11-23 · Hidradenitis Suppurativa
What this study did
NCT03248531 · UCB Biopharma SRL
2017-09-22 – 2019-02-21 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT01483599 · Janssen Inc.
2011-11-10 – 2013-08-05 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05640245 · MoonLake Immunotherapeutics AG
2022-12-13 – 2024-01-15 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT07423533 · Changchun GeneScience Pharmaceutical Co., Ltd.
2026-04-30 – 2028-12 · Rheumatoid Arthritis
What this study did
NCT02833350 · Genentech, Inc.
2016-09-09 – 2018-07-02 · Rheumatoid Arthritis
What this study did
NCT01373151 · CSL Behring
2011-06 – 2015-06 · Rheumatoid Arthritis
What this study did
NCT01264770 · AstraZeneca
2011-01 – 2013-08 · Rheumatoid Arthritis
What this study did
NCT02092961 · AstraZeneca
2011-02 – 2013-07 · Rheumatoid Arthritis
What this study did
NCT00595413 · EMD Serono
2007-09 – 2009-10 · Rheumatoid Arthritis
What this study did
NCT00550446 · Pfizer
2007-09 – 2009-01 · Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT06242652 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-03-19 – 2025-06-15 · Ankylosing Spondylitis
What this study did
NCT02929251 · Assistance Publique - Hôpitaux de Paris
2017-06-29 – 2022-01-29 · Uveitis, Biotherapy
What this study did
Phase 1 (20)
Psoriasis
Rheumatoid Arthritis
NCT03254810 · Synermore Biologics Co., Ltd.
2017-09-26 – 2018-07-17 · Arthritis, Rheumatoid
What this study did
Other / comorbidity
NCT05108259 · Prestige Biopharma Limited
2022-03-30 – 2027-08 · Healthy Volunteers
What this study did
NCT07181694 · Biocad
2025-03-12 – 2026-02-12 · Healthy Adult Male
What this study did
NCT07147257 · Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
2025-02-12 – 2025-05-29 · Healthy Participants
What this study did
NCT04439929 · Turgut İlaçları A.Ş.
2019-07-17 – 2020-01-16 · Healthy Participants
What this study did
NCT03970824 · Celltrion
2019-05-31 – 2020-01-15 · Healthy
What this study did
NCT03917628 · Sinocelltech Ltd.
2019-05-29 – 2019-11-04 · Healthy
What this study did
NCT03357939 · Shanghai Henlius Biotech
2017-01-12 – 2018-09-15 · Immune System Disorder
What this study did
NCT03579823 · Alvotech Swiss AG
2018-05-21 – 2018-08-24 · Healthy Volunteers
What this study did
NCT02912247 · Innovent Biologics (Suzhou) Co. Ltd.
2016-10-27 – 2017-09-22 · Healthy
What this study did
NCT02927353 · Meiji Seika Pharma Co., Ltd.
2016-08 – 2017-01-17 · Healthy Volunteer
What this study did
NCT05995691 · Amgen
2014-11-24 – 2015-12-04 · Healthy Volunteers
What this study did
NCT02395055 · Biocad
2015-06 – 2015-10 · Healthy
What this study did
NCT02472912 · Mylan Inc.
2014-12 – 2015-06 · Healthy Volunteers
What this study did
NCT02206867 · LG Life Sciences
2014-08 – 2015-02 · Healthy Subjects
What this study did
NCT03014947 · Fresenius Kabi SwissBioSim GmbH
2014-05 – 2014-12 · Healthy Subjects
What this study did
NCT02045979 · Boehringer Ingelheim
2014-01-31 – 2014-06-20 · Healthy
What this study did
NCT01870986 · Pfizer
2013-05 – 2014-02 · Healthy
What this study did
NCT01505491 · Boehringer Ingelheim
2011-12-01 – 2012-07-01 · Healthy
What this study did
Phase 4 (16)
Psoriatic Arthritis
NCT03151551 · Eli Lilly and Company
2017-08-24 – 2019-09-04 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05502731 · Leiden University Medical Center
2022-10 – 2025-10 · Rheumatoid Arthritis
What this study did
NCT06527534 · Universita di Verona
2024-07-15 – 2025-09-15 · Rheumatoid Arthritis
What this study did
NCT04255134 · St George's, University of London
2020-09-07 – 2022-10-26 · Rheumatoid Arthritis
What this study did
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
NCT02092467 · Pfizer
2014-03-14 – 2020-07-22 · Arthritis, Rheumatoid
What this study did
NCT02557100 · Bristol-Myers Squibb
2015-11-19 – 2019-03-28 · Rheumatoid Arthritis
What this study did
NCT01021735 · University of Glasgow
2010-04 – 2015-04 · Rheumatoid Arthritis
What this study did
NCT00808509 · AbbVie (prior sponsor, Abbott)
2009-01 – 2012-09 · Arthritis, Rheumatoid
What this study did
NCT01119859 · Hoffmann-La Roche
2010-05 – 2012-01 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05313620 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2022-04-01 – 2026-06-11 · Ulcerative Colitis, Thromboembolism
What this study did
NCT04131322 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2019-10-10 – 2020-06-08 · Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT07013838 · Chinese SLE Treatment And Research Group
2025-06-15 – 2028-03-31 · Takayasu Arteritis (TAK)
What this study did
NCT02187055 · Pfizer
2014-08 – 2016-12 · Rhematoid Arthritis
What this study did
Appears in other studies (9)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Psoriasis
NCT05073315 · Amgen
2021-10-04 – 2022-12-19 · Plaque Psoriasis
What this study did
Rheumatoid Arthritis
NCT04230213 · Pfizer
2020-01-13 – 2021-06-22 · Rheumatoid Arthritis
What this study did
Phase 2 (1)
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
Phase 4 (5)
Crohn's Disease
NCT03220841 · St Vincent's Hospital Melbourne
2017-10-09 – 2021-09 · Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel
What this study did
NCT00517296 · Vanderbilt University Medical Center
2008-01 – 2015-12 · Crohn Disease, Rectal Fistula
What this study did
Hidradenitis Suppurativa
NCT03221621 · Erasmus Medical Center
2018-07-31 – 2022-07-31 · Hidradenitis Suppurativa
What this study did
Ulcerative Colitis
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT01895764 · University Hospital, Tours
2013-03-20 – 2015-04-27 · Ankylosing Spondylitis
What this study did
Early phase / not applicable (1)
Psoriasis
NCT05503875 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-01-01 – 2027-12-31 · Immunoclassification, Psoriasis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Adalimumab (Humira): this drugApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9)
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3%
NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19%
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results).
NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results).
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002
NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Reliable signal
NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005)
NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphanot yet graded
NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants
NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002.
NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results).
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Partial signalNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5)
NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo.
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/FPartial signal
NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52).
NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled)
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
VunakizumabPhase 3Monoclonal antibodyIL-17Partial signal
NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively
ZasocitinibPhase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-10374Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(32 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Humira (adalimumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 2Behcet's UveitisNot yet recruiting
Est. primary completion 2026-11 · NCT05874505 · CT.gov ↗
What to watch
December 2026 (2)
Early phase / not applicablePsoriatic ArthritisNot yet recruiting
Est. primary completion 2026-12-30 · NCT07398651 · CT.gov ↗
What to watch
Phase 4UveitisNot yet recruiting
Est. primary completion 2026-12-31 · NCT05105347 · CT.gov ↗
What to watch
2027 (16)
January 2027 (2)
Phase 1/2Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VIActive not recruiting
Est. primary completion 2027-01 · NCT03153319 · CT.gov ↗
What to watch
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2Tuberculous Meningitis, HIV I InfectionRecruiting
Est. primary completion 2027-06 · NCT05590455 · CT.gov ↗
What to watch
Phase 1Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson SyndromeNot yet recruiting
Est. primary completion 2027-06-01 · NCT06926478 · CT.gov ↗
What to watch
Phase 3Non-Infectious UveitisNot yet recruiting
Est. primary completion 2027-06-01 · NCT06258915 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-28 · NCT06045754 · CT.gov ↗
What to watch
Phase 2Behcet Syndrome, Intestinal TypeRecruiting
Est. primary completion 2027-06-30 · NCT06849908 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Relapsing PolychondritisRecruiting
Est. primary completion 2027-07 · NCT06941376 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-07-30 · NCT05928039 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Ankylosing SpondylitisNot yet recruiting
Est. primary completion 2027-08 · NCT06833112 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Ulcerative ColitisActive not recruiting
Est. primary completion 2027-09 · NCT06257875 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-10-31 · NCT06180382 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2Inflammatory Arthritis, Immune-related Adverse EventRecruiting
Est. primary completion 2027-12 · NCT06037811 · CT.gov ↗
What to watch
Early phase / not applicableTakayasu ArteritisRecruiting
Est. primary completion 2027-12-15 · NCT07491913 · CT.gov ↗
What to watch
Phase 1/2Crohn's DiseaseNot yet recruiting
Est. primary completion 2027-12-31 · NCT07258641 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisActive not recruiting
Est. primary completion 2027-12-31 · NCT06440629 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
April 2028 (2)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2028-04 · NCT07529925 · CT.gov ↗
What to watch
Phase 2Benign Prostatic Hyperplasia (BPH)Recruiting
Est. primary completion 2028-04-01 · NCT06062875 · CT.gov ↗
What to watch
December 2028 (2)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT07510191 · CT.gov ↗
What to watch
Early phase / not applicableNon-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, PanuveitisNot yet recruiting
Est. primary completion 2028-12-31 · NCT07913750 · CT.gov ↗
What to watch
2029 (4)
August 2029 (1)
Phase 2REM Sleep Behavior DisorderRecruiting
Est. primary completion 2029-08-01 · NCT06996652 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Folliculitis Decalvans (FD)Not yet recruiting
Est. primary completion 2029-11-01 · NCT07268534 · CT.gov ↗
What to watch
Phase 4Juvenile Idiopathic Arthritis (JIA)Not yet recruiting
Est. primary completion 2029-11-11 · NCT07904780 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Uveitis, Chronic DiseaseNot yet recruiting
Est. primary completion 2029-12 · NCT06390436 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 1/2Type 1 Diabetes, New OnsetRecruiting
Est. primary completion 2030-04-15 · NCT07061574 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, AnteriorNot yet recruiting
Est. primary completion 2030-05 · NCT07699107 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2Major Depressive Disorder (MDD)Recruiting
Est. primary completion 2031-07 · NCT07845604 · CT.gov ↗
What to watch

See the full readout calendar ↗